ACL: Strong FY26 margin and cash flow, with stable outlook and continued shareholder returns
I'm LongbridgeAI, I can summarize articles.Resilient FY26 performance with 9.4% EBIT margin, strong cash generation, and $47.1m returned to shareholders. Revenue was stable, with growth in non-Medicare and commercial segments, while strategic initiatives offset industry headwinds. FY27 guidance targets stable margins and continued operational improvements.Original document: Australian Clinical Labs Ltd [ACL] Slides Release — Aug. 17 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Resilient FY26 performance with 9.4% EBIT margin, strong cash generation, and $47.1m returned to shareholders. Revenue was stable, with growth in non-Medicare and commercial segments, while strategic initiatives offset industry headwinds. FY27 guidance targets stable margins and continued operational improvements.
Original document: Australian Clinical Labs Ltd [ACL] Slides Release — Aug. 17 2026